Addressing HPV vaccine myths: practical information for healthcare providers

References

• Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2007;56:1–24.
   PubMedGoogle Scholar
• Centers for Disease Control and Prevention. FDA licensure of quadrivalent human papillomavirus vaccine (HPV4, Gardasil) for use in males and guidance from the Advisory Committee on Immunization Practices (ACIP). MMWR Morb Mortality Weekly Rep. 2010;59(20):630–32.
   PubMedGoogle Scholar
• Walker TY, Elam-Evans LD, Yankey D, Markowitz LE, Williams CL, Mbaeyi SA, Fredua B, Stokley S. National, regional, state, and selected local area vaccination coverage among adolescents aged 13-17 years - United States, 2017. MMWR Morb Mortality Weekly Rep. 2018;67(33):909–17. doi:10.15585/mmwr.mm6733a1.
   PubMed Web of Science ®Google Scholar
• MacDonald NE. Vaccine hesitancy: definition, scope and determinants. Vaccine. 2015;33(34):4161–64. doi:10.1016/j.vaccine.2015.04.036.
   PubMed Web of Science ®Google Scholar
• Larson HJ, de Figueiredo A, Xiahong Z, Schulz WS, Verger P, Johnston IG, Cook AR, Jones NS. The state of vaccine confidence 2016: global insights through a 67-country survey. EBioMedicine. 2016;12:295–301. doi:10.1016/j.ebiom.2016.08.042.
   PubMed Web of Science ®Google Scholar
• Larson HJ. The state of vaccine confidence. Lancet. 2018;392(10161):2244–46. doi:10.1016/S0140-6736(18)32608-4.
   PubMed Web of Science ®Google Scholar
• D’Alessandro A, Napolitano F, D’Ambrosio A, Angelillo IF. Vaccination knowledge and acceptability among pregnant women in Italy. Hum Vaccin Immunother. 2018;14(7):1573–79. doi:10.1080/21645515.2018.1483809.
   PubMed Web of Science ®Google Scholar
• Napolitano F, D’Alessandro A, Angelillo IF. Investigating Italian parents’ vaccine hesitancy: A cross-sectional survey. Hum Vaccin Immunother. 2018;14(7):1558–65. doi:10.1080/21645515.2018.1463943.
   PubMed Web of Science ®Google Scholar
• Napolitano F, Gualdieri L, Santagati G, Angelillo IF. Violence experience among immigrants and refugees: a cross-sectional study in Italy. Biomed Res Int. 2018;2018:7949483. doi:10.1155/2018/7949483.
   PubMed Web of Science ®Google Scholar
• Williams SE. What are the factors that contribute to parental vaccine-hesitancy and what can we do about it? Hum Vaccin Immunother. 2014;10(9):2584–96. doi:10.4161/hv.28596.
   PubMed Web of Science ®Google Scholar
• Roberts JR, Thompson D, Rogacki B, Hale JJ, Jacobson RM, Opel DJ, Darden PM. Vaccine hesitancy among parents of adolescents and its association with vaccine uptake. Vaccine. 2015;33(14):1748–55. doi:10.1016/j.vaccine.2015.01.068.
   PubMed Web of Science ®Google Scholar
• Killian M, Detoc M, Berthelot P, Charles R, Gagneux-Brunon A, Lucht F, Pulcini C, Barbois S, Botelho-Nevers E. Vaccine hesitancy among general practitioners: evaluation and comparison of their immunisation practice for themselves, their patients and their children. Eur J Clin Microbiol Infect Dis. 2016;35(11):1837–43. doi:10.1007/s10096-016-2735-4.
   PubMed Web of Science ®Google Scholar
• Napolitano F, Napolitano P, Liguori G, Angelillo IF. Human papillomavirus infection and vaccination: knowledge and attitudes among young males in Italy. Hum Vaccin Immunother. 2016;12(6):1504–10. doi:10.1080/21645515.2016.1156271.
   PubMed Web of Science ®Google Scholar
• Napolitano F, Gualdieri L, Santagati G, Angelillo IF. Knowledge and attitudes toward HPV infection and vaccination among immigrants and refugees in Italy. Vaccine. 2018;36(49):7536–41. doi:10.1016/j.vaccine.2018.10.050.
   PubMed Web of Science ®Google Scholar
• Napolitano F, Navaro M, Vezzosi L, Santagati G, Angelillo IF. Primary care pediatricians’ attitudes and practice towards HPV vaccination: a nationwide survey in Italy. PLoS One. 2018;13(3):e0194920. doi:10.1371/journal.pone.0194920.
   PubMed Web of Science ®Google Scholar
• Patel PR, Berenson AB. Sources of HPV vaccine hesitancy in parents. Hum Vaccin Immunother. 2013;9(12):2649–53. doi:10.4161/hv.26224.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, Magnus BE, Reiter PL, McRee AL, Dempsey AF, Brewer NT. The Vaccination Confidence Scale: a brief measure of parents’ vaccination beliefs. Vaccine. 2014;32(47):6259–65. doi:10.1016/j.vaccine.2014.09.007.
   PubMed Web of Science ®Google Scholar
• McRee AL, Gilkey MB, Dempsey AF. HPV vaccine hesitancy: findings from a statewide survey of health care providers. J Pediatr Health Care. 2014;28(6):541–49. doi:10.1016/j.pedhc.2014.05.003.
   PubMed Web of Science ®Google Scholar
• Collange F, Fressard L, Pulcini C, Sebbah R, Peretti-Watel P, Verger P. General practitioners’ attitudes and behaviors toward HPV vaccination: a French national survey. Vaccine. 2016;34(6):762–68. doi:10.1016/j.vaccine.2015.12.054.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, Reiter PL, Magnus BE, McRee AL, Dempsey AF, Brewer NT. Validation of the vaccination confidence scale: a brief measure to identify parents at risk for refusing adolescent vaccines. Acad Pediatr. 2016;16(1):42–49. doi:10.1016/j.acap.2015.06.007.
   PubMed Web of Science ®Google Scholar
• Gilkey MB, Calo WA, Marciniak MW, Brewer NT. Parents who refuse or delay HPV vaccine: differences in vaccination behavior, beliefs, and clinical communication preferences. Hum Vaccin Immunother. 2017;13(3):680–86. doi:10.1080/21645515.2016.1247134.
   PubMed Web of Science ®Google Scholar
• Palmeri S, Costantino C, D’Angelo C, Casuccio N, Ventura G, Vitale F, Pojero F, Casuccio A. HPV vaccine hesitancy among parents of female adolescents: a pre-post interventional study. Public Health. 2017;150:84–86. doi:10.1016/j.puhe.2017.05.009.
   PubMed Web of Science ®Google Scholar
• Thompson EL, Rosen BL, Vamos CA, Kadono M, Daley EM. Human papillomavirus vaccination: what are the reasons for nonvaccination among U.S. adolescents? J Adolesc Health. 2017;61(3):288–93. doi:10.1016/j.jadohealth.2017.05.015.
   PubMed Web of Science ®Google Scholar
• Hanson KE, Koch B, Bonner K, McRee AL, Basta NE. National trends in parental human papillomavirus vaccination intentions and reasons for hesitancy, 2010–2015. Clin Infect Dis. 2018;67(7):1018–26. doi:10.1093/cid/ciy232.
   PubMed Web of Science ®Google Scholar
• Restivo V, Costantino C, Fazio TF, Casuccio N, D'Angelo C, Vitale F, Casuccio A. Factors associated with HPV vaccine refusal among young adult women after ten years of vaccine implementation. Int J Environ Res Public Health. 2018;15(4). doi:10.3390/ijerph15061188.
   Web of Science ®Google Scholar
• Shay LA, Baldwin AS, Betts AC, Marks EG, Higashi RT, Street RL, Persaud D, Tiro JA. Parent-provider communication of HPV vaccine hesitancy. Pediatrics. 2018;141(6):e20172312. doi:10.1542/peds.2017-2312.
   PubMed Web of Science ®Google Scholar
• Holman DM, Benard V, Roland KB, Watson M, Liddon N, Stokley S. Barriers to human papillomavirus vaccination among US adolescents: a systematic review of the literature. JAMA Pediatr. 2014;168(1):76–82. doi:10.1001/jamapediatrics.2013.2752.
   PubMed Web of Science ®Google Scholar
• Ferrer HB, Trotter C, Hickman M, Audrey S. Barriers and facilitators to HPV vaccination of young women in high-income countries: a qualitative systematic review and evidence synthesis. BMC Public Health. 2014;14:700. doi:10.1186/1471-2458-14-700.
   PubMed Web of Science ®Google Scholar
• Garbutt JM, Dodd S, Walling E, Lee AA, Kulka K, Lobb R. Barriers and facilitators to HPV vaccination in primary care practices: a mixed methods study using the Consolidated Framework for Implementation Research. BMC Fam Pract. 2018;19(1):53. doi:10.1186/s12875-018-0787-5.
   PubMed Web of Science ®Google Scholar
• Seyferth ER, Bratic JS, Bocchini JA, Jr. Human papillomavirus epidemiology and vaccine recommendations: selected review of the recent literature. Curr Opin Pediatr. 2016;28(3):400–06. doi:10.1097/MOP.0000000000000354.
   PubMed Web of Science ®Google Scholar
• Schiller JT, Castellsague X, Garland SM. A review of clinical trials of human papillomavirus prophylactic vaccines. Vaccine. 2012;30(Suppl 5):F123–138. doi:10.1016/j.vaccine.2012.04.108.
   PubMed Web of Science ®Google Scholar
• Markowitz LE, Gee J, Chesson H, Stokley S. Ten years of human papillomavirus vaccination in the United States. Acad Pediatr. 2018;18(2s):S3–s10. doi:10.1016/j.acap.2017.09.014.
   PubMed Web of Science ®Google Scholar
• Gee J, Weinbaum C, Sukumaran L, Markowitz LE. Quadrivalent HPV vaccine safety review and safety monitoring plans for nine-valent HPV vaccine in the United States. Hum Vaccin Immunother. 2016;12(6):1406–17. doi:10.1080/21645515.2016.1168952.
   PubMed Web of Science ®Google Scholar
• Zimet GD, Rosberger Z, Fisher WA, Perez S, Stupiansky NW. Beliefs, behaviors and HPV vaccine: correcting the myths and the misinformation. Prev Med. 2013;57(5):414–18. doi:10.1016/j.ypmed.2013.05.013.
   PubMed Web of Science ®Google Scholar
• Three Rivers AHEC. Addressing HPV vaccine myths and hesitance. 2017 [ accessed 2018 Sept 27]. https://www.eventbrite.com/e/addressing-hpv-vaccine-hesitancy-and-myths-registration-35214570729.
   Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Ault KA, Giuliano AR, Wheeler CM, Koutsky LA, Malm C, Lehtinen M, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet. 2005;6(5):271–78. doi:10.1016/S1470-2045(05)70101-7.
   PubMed Web of Science ®Google Scholar
• Villa LL, Costa RL, Petta CA, Andrade RP, Paavonen J, Iversen O-E, Olsson S-E, Høye J, Steinwall M, Riis-Johannessen G, et al. High sustained efficacy of a prophylactic quadrivalent human papillomavirus types 6/11/16/18 L1 virus-like particle vaccine through 5 years of follow-up. Br J Cancer. 2006;95(11):1459–66. doi:10.1038/sj.bjc.6603469.
   PubMed Web of Science ®Google Scholar
• The FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl J Med. 2007;356(19):1915–27. doi:10.1056/NEJMoa061741.
   PubMed Web of Science ®Google Scholar
• Ault KA. Effect of prophylactic human papillomavirus L1 virus-like-particle vaccine on risk of cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ: a combined analysis of four randomised clinical trials. Lancet. 2007;369(9576):1861–68. doi:10.1016/S0140-6736(07)60852-6.
   PubMed Web of Science ®Google Scholar
• Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GWK, Ferris DG, Steben M, Bryan J, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases. N Engl J Med. 2007;356(19):1928–43. doi:10.1056/NEJMoa061760.
   PubMed Web of Science ®Google Scholar
• Joura EA, Leodolter S, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Garland SM, Harper DM, Tang GWK, Ferris DG, et al. Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials. Lancet. 2007;369(9574):1693–702. doi:10.1016/S0140-6736(07)60777-6.
   PubMed Web of Science ®Google Scholar
• Olsson SE, Villa LL, Costa RL, Petta CA, Andrade RP, Malm C, Iversen O-E, Høye J, Steinwall M, Riis-Johannessen G, et al. Induction of immune memory following administration of a prophylactic quadrivalent human papillomavirus (HPV) types 6/11/16/18 L1 virus-like particle (VLP) vaccine. Vaccine. 2007;25(26):4931–39. doi:10.1016/j.vaccine.2007.03.049.
   PubMed Web of Science ®Google Scholar
• Joura EA, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, et al. HPV antibody levels and clinical efficacy following administration of a prophylactic quadrivalent HPV vaccine. Vaccine. 2008;26(52):6844–51. doi:10.1016/j.vaccine.2008.09.073.
   PubMed Web of Science ®Google Scholar
• Brown DR, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years. J Infect Dis. 2009;199(7):926–35. doi:10.1086/597307.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. A pooled analysis of continued prophylactic efficacy of quadrivalent human papillomavirus (Types 6/11/16/18) vaccine against high-grade cervical and external genital lesions. Cancer Prev Res (Phila). 2009;2(10):868–78. doi:10.1158/1940-6207.CAPR-09-0031.
   PubMed Web of Science ®Google Scholar
• Wheeler CM, Kjaer SK, Sigurdsson K, Iversen O-E, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, et al. The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16–26 years. J Infect Dis. 2009;199(7):936–44. doi:10.1086/597309.
   PubMed Web of Science ®Google Scholar
• Dillner J, Kjaer SK, Wheeler CM, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, et al. Four year efficacy of prophylactic human papillomavirus quadrivalent vaccine against low grade cervical, vulvar, and vaginal intraepithelial neoplasia and anogenital warts: randomised controlled trial. BMJ. 2010;341:c3493. doi:10.1136/bmj.c3493.
   PubMed Web of Science ®Google Scholar
• Castellsagué X, Muñoz N, Pitisuttithum P, Ferris D, Monsonego J, Ault K, Luna J, Myers E, Mallary S, Bautista OM, et al. End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24-45 years of age. Br J Cancer. 2011;105(1):28–37. doi:10.1038/bjc.2011.185.
   PubMed Web of Science ®Google Scholar
• Giuliano AR, Palefsky JM, Goldstone S, Moreira ED, Penny ME, Aranda C, Vardas E, Moi H, Jessen H, Hillman R, et al. Efficacy of quadrivalent HPV vaccine against HPV infection and disease in males. N Engl J Med. 2011;364(5):401–11. doi:10.1056/NEJMoa0909537.
   PubMed Web of Science ®Google Scholar
• Martin L Does the HPV vaccination prevent cervical cancer? You decide. 2015 [ accessed 2018 Sept 30]. https://thetruthaboutcancer.com/hpv-vaccination-cervical-cancer/.
   Google Scholar
• Melton M Another doctor testifies: ‘HPV vaccine does not protect against cancer’. 2013 [ accessed 2018 Sept 30]. http://www.activistpost.com/2013/09/another-doctor-testifies-hpv-vaccine.html.
   Google Scholar
• Mercola J Don’t give HPV vaccine to your daughter – despite what your doctor says. 2010. [ accessed 2018 Sept 30]. https://articles.mercola.com/sites/articles/archive/2010/11/05/gardasil-vaccine-is-a-flop-for-good-reasons.aspx.
   Google Scholar
• Brescia RJ, Jenson AB, Lancaster WD, Kurman RJ. The role of human papillomaviruses in the pathogenesis and histologic classification of precancerous lesions of the cervix. Hum Pathol. 1986;17:552–59.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Schiffman M, Kjaer S, Villa LL. Chapter 5: updating the natural history of HPV and anogenital cancer. Vaccine. 2006;24(Suppl 3):S3/42–51. doi:10.1016/j.vaccine.2006.06.018.
   PubMed Web of Science ®Google Scholar
• Moscicki AB, Schiffman M, Burchell A, Albero G, Giuliano AR, Goodman MT, Kjaer SK, Palefsky J. Updating the natural history of human papillomavirus and anogenital cancers. Vaccine. 2012;30(Suppl 5):F24–33. doi:10.1016/j.vaccine.2012.05.089.
   PubMed Web of Science ®Google Scholar
• Jaisamrarn U, Castellsague X, Garland SM, Naud P, Palmroth J, Del Rosario-Raymundo MR, Wheeler CM, Salmerón J, Chow S-N, Apter D, et al. Natural history of progression of HPV infection to cervical lesion or clearance: analysis of the control arm of the large, randomised PATRICIA study. PLoS One. 2013;8(11):e79260. doi:10.1371/journal.pone.0079260.
   PubMed Web of Science ®Google Scholar
• Ostor AG. Natural history of cervical intraepithelial neoplasia: a critical review. Int J Gynecol Pathol. 1993;12:186–92.
   PubMed Web of Science ®Google Scholar
• Bednarczyk RA, Figueroa-Downing D, Ault K. Why is it appropriate to recommend human papillomavirus vaccination as cervical cancer prevention? Am J Obstet Gynecol. 2016;214(4):490–93. doi:10.1016/j.ajog.2015.10.920.
   PubMed Web of Science ®Google Scholar
• Merck & Co. Gardasil 9 package insert. 2018 [ accessed 2018 Sept 27]. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm426457.pdf.
   Google Scholar
• Merck & Co. Gardasil package insert. 2011 [ accessed 2018 Sept 27]. https://www.fda.gov/downloads/biologicsbloodvaccines/vaccines/approvedproducts/ucm111263.pdf.
   Google Scholar
• Markowitz LE, Dunne EF, Saraiya M, Chesson HW, Curtis CR, Gee J, Bocchini JA Jr, Unger ERHuman papillomavirus vaccination: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2014;63(Rr–05):1–30.
   Google Scholar
• Oakley F, Desouki MM, Pemmaraju M, Gargano JM, Markowitz LE, Steinau M, Unger ER, Zhu Y, Fadare O, Griffin MR. Trends in high-grade cervical cancer precursors in the human papillomavirus vaccine era. Am J Prev Med. 2018;55(1):19–25. doi:10.1016/j.amepre.2018.03.015.
   PubMed Web of Science ®Google Scholar
• Guo F, Cofie LE, Berenson AB. Cervical cancer incidence in young U.S. females after human papillomavirus vaccine introduction. Am J Prev Med. 2018;55(2):197–204. doi:10.1016/j.amepre.2018.03.013.
   PubMed Web of Science ®Google Scholar
• Kjaer SK, Nygard M, Dillner J, Brooke Marshall J, Radley D, Li M, Munk C, Hansen BT, Sigurdardottir LG, Hortlund M, et al. A 12-year follow-up on the long-term effectiveness of the quadrivalent human papillomavirus vaccine in 4 nordic countries. Clin Infect Dis. 2018;66(3):339–45. doi:10.1093/cid/cix797.
   PubMed Web of Science ®Google Scholar
• Winer RL, Kiviat NB, Hughes JP, Adam DE, Lee S-K, Kuypers JM, Koutsky LA. Development and duration of human papillomavirus lesions, after initial infection. J Infect Dis. 2005;191(5):731–38. doi:10.1086/427557.
   PubMed Web of Science ®Google Scholar
• Ali H, Donovan B, Wand H, Read TR, Regan DG, Grulich AE, Fairley CK, Guy RJ. Genital warts in young Australians five years into national human papillomavirus vaccination programme: national surveillance data. BMJ. 2013;346:f2032. doi:10.1136/bmj.f1164.
   PubMed Web of Science ®Google Scholar
• Bauer HM, Wright G, Chow J. Evidence of human papillomavirus vaccine effectiveness in reducing genital warts: an analysis of California public family planning administrative claims data, 2007–2010. Am J Public Health. 2012;102(5):833–35. doi:10.2105/AJPH.2011.300465.
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Munk C, Kjaer SK. Strongly decreased risk of genital warts after vaccination against human papillomavirus: nationwide follow-up of vaccinated and unvaccinated girls in Denmark. Clin Infect Dis. 2013;57(7):929–34. doi:10.1093/cid/cit436.
   PubMed Web of Science ®Google Scholar
• Blomberg M, Dehlendorff C, Sand C, Kjaer SK. Dose-related differences in effectiveness of human papillomavirus vaccination against genital warts: a nationwide study of 550,000 young girls. Clin Infect Dis. 2015;61(5):676–82. doi:10.1093/cid/civ364.
   PubMed Web of Science ®Google Scholar
• Mariani L, Vici P, Suligoi B, Checcucci-Lisi G, Drury R. Early direct and indirect impact of quadrivalent HPV (4HPV) vaccine on genital warts: a systematic review. Adv Ther. 2015;32(1):10–30. doi:10.1007/s12325-015-0178-4.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Legler A, Hanchate A. Trends in male and female genital warts among adolescents in a safety-net health care system 2004–2013: correlation with introduction of female and male human papillomavirus vaccination. Sex Transm Dis. 2015;42(12):665–68. doi:10.1097/OLQ.0000000000000369.
   PubMed Web of Science ®Google Scholar
• Perkins RB, Lin M, Wallington SF, Hanchate A. Impact of number of human papillomavirus vaccine doses on genital warts diagnoses among a national cohort of U.S. adolescents. Sex Transm Dis. 2017;44(6):365–70. doi:10.1097/OLQ.0000000000000615.
   PubMed Web of Science ®Google Scholar
• Gertig DM, Brotherton JM, Saville M. Measuring human papillomavirus (HPV) vaccination coverage and the role of the National HPV Vaccination Program Register, Australia. Sex Health. 2011;8(2):171–78. doi:10.1071/SH10001.
   PubMed Web of Science ®Google Scholar
• Liang JL, Tiwari T, Moro P, Messonnier NE, Reingold A, Sawyer M, Clark TA. Prevention of pertussis, tetanus, and diphtheria with vaccines in the United States: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2018;67(2):1–44. doi:10.15585/mmwr.rr6702a1.
   PubMed Web of Science ®Google Scholar
• Cohn AC, MacNeil JR, Clark TA, Ortega-Sanchez IR, Briere EZ, Meissner HC, Baker CJ, Messonnier NE. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62(Rr–2):1–28.
   PubMed Web of Science ®Google Scholar
• Robinson CL, Romero JR, Kempe A, Pellegrini C, Szilagyi P. Advisory committee on immunization practices recommended immunization schedule for children and adolescents aged 18 years or younger - United States, 2018. MMWR Morb Mortality Weekly Rep. 2018;67(5):156–57. doi:10.15585/mmwr.mm6705e2.
   PubMed Web of Science ®Google Scholar
• Meites E, Kempe A, Markowitz LE. Use of a 2-dose schedule for human papillomavirus vaccination - updated recommendations of the advisory committee on immunization practices. MMWR Morb Mortality Weekly Rep. 2016;65(49):1405–08. doi:10.15585/mmwr.mm6549a5.
   PubMed Web of Science ®Google Scholar
• Petrosky E, Bocchini JA, Jr, Hariri S, Chesson H, Curtis CR, Saraiya M, Unger ER, Markowitz LE. Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vaccination recommendations of the advisory committee on immunization practices. MMWR Morb Mortality Weekly Rep. 2015;64:300–04.
   PubMed Web of Science ®Google Scholar
• Mercola J Avoidance of HPV vaccine may contribute to increase of some cancers? 2013 [ accessed 2018 Sept 27]. https://articles.mercola.com/sites/articles/archive/2013/01/24/hpv-vaccine-averting-cancer-unproven.aspx.
   Google Scholar
• Gustafsson L, Ponten J, Bergstrom R, Adami HO. International incidence rates of invasive cervical cancer before cytological screening. Int J Cancer. 1997;71:159–65.
   PubMed Web of Science ®Google Scholar
• Gustafsson L, Ponten J, Zack M, Adami HO. International incidence rates of invasive cervical cancer after introduction of cytological screening. Cancer Causes Control. 1997;8(5):755–63. doi:10.1023/A:1018435522475.
   PubMed Web of Science ®Google Scholar
• Bruni L, Albero G, Serrano B, Mena M, Gómez D, Muñoz J, Bosch FX, de Sanjosé S. ICO/IARC Information Centre on HPV and Cancer (HPV Information Centre). Human papillomavirus and related diseases in the world. Summary Report. 2018 [ accessed 2018 Sept 27]. http://hpvcentre.net/statistics/reports/XWX.pdf.
   Google Scholar
• Van Dyne EA, Henley SJ, Saraiya M, Thomas CC, Markowitz LE, Benard VB. Trends in human papillomavirus-associated cancers - United States, 1999-2015. MMWR Morb Mortality Weekly Rep. 2018;67(33):918–24. doi:10.15585/mmwr.mm6733a2.
   PubMed Web of Science ®Google Scholar
• O'Leary ST, Lockhart S, Barnard J, Furniss A, Dickinson M, Dempsey AF, Stokley S, Federico S, Bronsert M, Kempe A. Exploring facilitators and barriers to initiation and completion of the Human Papillomavirus (HPV) vaccine series among parents of girls in a safety net system. Int J Environ Res Public Health. 2018;15:2. doi:10.3390/ijerph15061188.
   Web of Science ®Google Scholar
• Bednarczyk RA, Birkhead GS, Morse DL, Doleyres H, McNutt LA. Human papillomavirus vaccine uptake and barriers: association with perceived risk, actual risk and race/ethnicity among female students at a New York State university, 2010. Vaccine. 2011;29(17):3138–43. doi:10.1016/j.vaccine.2011.02.045.
   PubMed Web of Science ®Google Scholar
• Hopfer S, Clippard JR. College women’s HPV vaccine decision narratives. Qual Health Res. 2011;21(2):262–77. doi:10.1177/1049732310383868.
   PubMed Web of Science ®Google Scholar
• Marchand E, Glenn BA, Bastani R. Low HPV vaccine coverage among female community college students. J Community Health. 2012;37(6):1136–44. doi:10.1007/s10900-012-9572-x.
   PubMed Web of Science ®Google Scholar
• Telegraph Reporters. Teenage girl dies five days after receiving HPV vaccine jab. 2016 [ accessed 2018 Sept 26]. https://www.telegraph.co.uk/news/2016/05/10/teenage-girl-dies-five-days-after-receiving-hpv-vaccine-jab/.
   Google Scholar
• Huff E. Healthy 12-year-old girl dies shortly after receiving HPV vaccine. 2014 [ accessed 2018 Sept 26]. http://www.naturalnews.com/047024_HPV_vaccine_Gardasil_Geoffrey_Swain.html.
   Google Scholar
• Baker B, Eca Guimaraes L, Tomljenovic L, Agmon-Levin N, Shoenfeld Y. The safety of human papilloma virus-blockers and the risk of triggering autoimmune diseases. Expert Opin Drug Saf. 2015;14(9):1387–94. doi:10.1517/14740338.2015.1073710.
   PubMed Web of Science ®Google Scholar
• Bizjak M, Bruck O, Kanduc D, Praprotnik S, Shoenfeld Y. Vaccinations and secondary immune thrombocytopenia with antiphospholipid antibodies by human papillomavirus vaccine. Semin Hematol. 2016;53(Suppl 1):S48–50. doi:10.1053/j.seminhematol.2016.04.014.
   PubMed Web of Science ®Google Scholar
• Dahan S, Tomljenovic L, Shoenfeld Y. Postural Orthostatic Tachycardia Syndrome (POTS)–A novel member of the autoimmune family. Lupus. 2016;25(4):339–42. doi:10.1177/0961203316629558.
   PubMed Web of Science ®Google Scholar
• Gatto M, Agmon-Levin N, Soriano A, Manna R, Maoz-Segal R, Kivity S, Doria A, Shoenfeld Y. Human papillomavirus vaccine and systemic lupus erythematosus. Clin Rheumatol. 2013;32(9):1301–07. doi:10.1007/s10067-013-2266-7.
   PubMed Web of Science ®Google Scholar
• Inbar R, Weiss R, Tomljenovic L, Arango M-T, Deri Y, Shaw CA, Chapman J, Blank M, Shoenfeld Y. Behavioral abnormalities in female mice following administration of aluminum adjuvants and the human papillomavirus (HPV) vaccine Gardasil. Immunol Res. 2017;65(1):136–49. doi:10.1007/s12026-016-8826-6.
   PubMed Web of Science ®Google Scholar
• Pellegrino P, Perrone V, Pozzi M, Carnovale C, Perrotta C, Clementi E, Radice S. The epidemiological profile of ASIA syndrome after HPV vaccination: an evaluation based on the Vaccine Adverse Event Reporting Systems. Immunol Res. 2015;61(1–2):90–96. doi:10.1007/s12026-014-8567-3.
   PubMed Web of Science ®Google Scholar
• Segal Y, Calabro M, Kanduc D, Shoenfeld Y. Human papilloma virus and lupus: the virus, the vaccine and the disease. Curr Opin Rheumatol. 2017;29(4):331–42. doi:10.1097/BOR.0000000000000398.
   PubMed Web of Science ®Google Scholar
• Segal Y, Dahan S, Calabro M, Kanduc D, Shoenfeld Y. HPV and systemic lupus erythematosus: a mosaic of potential crossreactions. Immunol Res. 2017;65(2):564–71. doi:10.1007/s12026-016-8890-y.
   PubMed Web of Science ®Google Scholar
• Shoenfeld Y. HPV vaccines and autoimmune diseases. J Intern Med. 2012;272(1):98; author reply 99. doi:10.1111/j.1365-2796.2012.02537.x.
   PubMed Web of Science ®Google Scholar
• Colafrancesco S, Perricone C, Tomljenovic L, Shoenfeld Y. Human papilloma virus vaccine and primary ovarian failure: another facet of the autoimmune/inflammatory syndrome induced by adjuvants. Am J Reprod Immunol. 2013;70(4):309–16. doi:10.1111/aji.12151.
   PubMed Web of Science ®Google Scholar
• DeLong G. A lowered probability of pregnancy in females in the USA aged 25-29 who received a human papillomavirus vaccine injection. J Toxicol Environ Health A. 2018;81(14):661–74. doi:10.1080/15287394.2018.1477640.
   PubMed Web of Science ®Google Scholar
• Geier DA, Geier MR. Quadrivalent human papillomavirus vaccine and autoimmune adverse events: a case-control assessment of the vaccine adverse event reporting system (VAERS) database. Immunol Res. 2017;65(1):46–54. doi:10.1007/s12026-016-8815-9.
   PubMed Web of Science ®Google Scholar
• Gruber N, Shoenfeld Y. A link between human papilloma virus vaccination and primary ovarian insufficiency: current analysis. Curr Opin Obstet Gynecol. 2015;27(4):265–70. doi:10.1097/GCO.0000000000000183.
   PubMed Web of Science ®Google Scholar
• Little DT, Ward HR. Premature ovarian failure 3 years after menarche in a 16-year-old girl following human papillomavirus vaccination. BMJ Case Rep. 2012;2012. doi: 10.1136/bcr-2012-006879.
   PubMedGoogle Scholar
• Little DT, Ward HR. Adolescent premature ovarian insufficiency following human papillomavirus vaccination: a case series seen in general practice. J Investig Med High Impact Case Rep. 2014;2(4):2324709614556129. doi:10.1177/2324709614556129.
   Google Scholar
• Pellegrino P, Carnovale C, Perrone V, Salvati D, Gentili M, Brusadelli T, Pozzi M, Antoniazzi S, Clementi E, Radice S. On the association between human papillomavirus vaccine and primary ovarian failure. Am J Reprod Immunol. 2014;71(4):293–94. doi:10.1111/aji.12190.
   PubMed Web of Science ®Google Scholar
• Arana JE, Harrington T, Cano M, Lewis P, Mba-Jonas A, Rongxia L, Stewart B, Markowitz LE, Shimabukuro TT. Post-licensure safety monitoring of quadrivalent human papillomavirus vaccine in the Vaccine Adverse Event Reporting System (VAERS), 2009-2015. Vaccine. 2018;36(13):1781–88. doi:10.1016/j.vaccine.2018.02.034.
   PubMed Web of Science ®Google Scholar
• Gee J, Naleway A, Shui I, Baggs J, Yin R, Li R, Kulldorff M, Lewis E, Fireman B, Daley MF, et al. Monitoring the safety of quadrivalent human papillomavirus vaccine: findings from the Vaccine Safety Datalink. Vaccine. 2011;29(46):8279–84. doi:10.1016/j.vaccine.2011.08.106.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Syncope after vaccination–United States, January 2005–July 2007. MMWR Morb Mortality Weekly Rep. 2008;57(17):457–60.
   PubMedGoogle Scholar
• Slade BA, Leidel L, Vellozzi C, Woo EJ, Hua W, Sutherland A, Izurieta HS, Ball R, Miller N, Braun MM, et al. Postlicensure safety surveillance for quadrivalent human papillomavirus recombinant vaccine. JAMA. 2009;302(7):750–57. doi:10.1001/jama.2009.1201.
   PubMed Web of Science ®Google Scholar
• McCarthy NL, Gee J, Sukumaran L, Weintraub E, Duffy J, Kharbanda EO, Baxter R, Irving S, King J, Daley MF, et al. Vaccination and 30-day mortality risk in children, adolescents, and young adults. Pediatrics. 2016;137(3):e20152970. doi:10.1542/peds.2015-2970.
   PubMed Web of Science ®Google Scholar
• Chao C, Klein NP, Velicer CM, Sy LS, Slezak JM, Takhar H, Ackerson B, Cheetham TC, Hansen J, Deosaransingh K, et al. Surveillance of autoimmune conditions following routine use of quadrivalent human papillomavirus vaccine. J Intern Med. 2012;271(2):193–203. doi:10.1111/j.1365-2796.2011.02467.x.
   PubMed Web of Science ®Google Scholar
• Liu EY, Smith LM, Ellis AK, Whitaker H, Law B, Kwong JC, Farrington P, Lévesque LE. Quadrivalent human papillomavirus vaccination in girls and the risk of autoimmune disorders: the Ontario Grade 8 HPV Vaccine Cohort Study. CMAJ. 2018;190(21):E648–E655. doi:10.1503/cmaj.170871.
   PubMed Web of Science ®Google Scholar
• Frisch M, Besson A, Clemmensen KKB, Valentiner-Branth P, Molbak K, Hviid A. Quadrivalent human papillomavirus vaccination in boys and risk of autoimmune diseases, neurological diseases and venous thromboembolism. Int J Epidemiol. 2018;47(2):634–41. doi:10.1093/ije/dyx273.
   PubMed Web of Science ®Google Scholar
• Arnheim-Dahlstrom L, Pasternak B, Svanstrom H, Sparen P, Hviid A. Autoimmune, neurological, and venous thromboembolic adverse events after immunisation of adolescent girls with quadrivalent human papillomavirus vaccine in Denmark and Sweden: cohort study. BMJ. 2013;347:f5906.
   PubMed Web of Science ®Google Scholar
• Hviid A, Svanstrom H, Scheller NM, Gronlund O, Pasternak B, Arnheim-Dahlstrom L. Human papillomavirus vaccination of adult women and risk of autoimmune and neurological diseases. J Intern Med. 2018;283(2):154–65. doi:10.1111/joim.12694.
   PubMed Web of Science ®Google Scholar
• Klein NP, Hansen J, Chao C, Velicer C, Emery M, Slezak J, Lewis N, Deosaransingh K, Sy L, Ackerson B, et al. Safety of quadrivalent human papillomavirus vaccine administered routinely to females. Arch Pediatr Adolesc Med. 2012;166(12):1140–48. doi:10.1001/archpediatrics.2012.1451.
   PubMed Web of Science ®Google Scholar
• Ackerson BK, Sy LS, Slezak J, Chao CR, Hechter RC, Takhar HS, Jacobsen SJ. Unmasking in an observational vaccine safety study: using type 2 diabetes mellitus as an example. Vaccine. 2015;33(46):6224–26. doi:10.1016/j.vaccine.2015.09.080.
   PubMed Web of Science ®Google Scholar
• Ho GY, Bierman R, Beardsley L, Chang CJ, Burk RD. Natural history of cervicovaginal papillomavirus infection in young women. N Engl J Med. 1998;338(7):423–28. doi:10.1056/NEJM199802123380703.
   PubMed Web of Science ®Google Scholar
• Winer RL, Hughes JP, Feng Q, Xi LF, Cherne S, O’Reilly S, Kiviat NB, Koutsky LA. Early natural history of incident, type-specific human papillomavirus infections in newly sexually active young women. Cancer Epidemiol Biomarkers Prev. 2011;20(4):699–707. doi:10.1158/1055-9965.EPI-10-1108.
   PubMed Web of Science ®Google Scholar
• Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA. Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students. Am J Epidemiol. 2003;157:218–26.
   PubMed Web of Science ®Google Scholar
• Brogan K Can pharma improve on nature? HPV vaccine vs natural infection [ accessed 2018 Sept 27]. https://kellybroganmd.com/can-pharma-improve-nature-hpv-vaccine-vs-natural-infection/.
   Google Scholar
• Mercola J. Learn all about HPV: an introduction [ accessed 2019 Jan 29]. https://articles.mercola.com/hpv.aspx.
   Google Scholar
• US Census Bureau. Annual estimates of the resident population for selected age groups by sex for the United States, states, counties, and puerto rico commonwealth and municipios: April 1, 2010 to July 1, 2017. 2018 [ accessed 2018 Sept 27]. https://factfinder.census.gov/faces/tableservices/jsf/pages/productview.xhtml?pid=PEP_2017_PEPAGESEX&prodType=table.
   Google Scholar
• Attkisson S Gardasil researcher speaks out. 2009 [ accessed 2018 Sept 26] https://www.cbsnews.com/news/gardasil-researcher-speaks-out/.
   Google Scholar
• Perkins RB, Clark JA, Apte G, Vercruysse JL, Sumner JJ, Wall-Haas CL, Rosenquist AW, Pierre-Joseph N. Missed opportunities for HPV vaccination in adolescent girls: a qualitative study. Pediatrics. 2014;134(3):e666–674. doi:10.1542/peds.2014-0442.
   PubMed Web of Science ®Google Scholar
• Rickman D Cervical cancer jab ‘gives youngsters green light for promiscuity’, charity LIFE says. 2012 [ accessed 2018 Sept 26]. https://www.huffingtonpost.co.uk/2012/07/24/hpv-vaccine-green-light-promiscuity-government-advisers_n_1697840.html?guccounter=1.
   Google Scholar
• Wolfson P CDC report: HPV-related cancers are on the rise. 2016 [ accessed 2018 Sept 26]. http://wtop.com/health/2016/07/cdc-hpv-related-cancers-rise/.
   Google Scholar
• Smith R, Motiuk D, Henry F, Pettipas G, Bouchard L, Chatlain M Alberta Bishops’ statement on Gardasil vaccine. 2008 [ accessed 2018 Sept 26]. http://hugyourkids.org/correspondence/HPV%20Alberta%20Bishops’%20Letter.pdf.
   Google Scholar
• Dobson SR, McNeil S, Dionne M, Dawar M, Ogilvie G, Krajden M, Sauvageau C, Scheifele DW, Kollmann TR, Halperin SA, et al. Immunogenicity of 2 doses of HPV vaccine in younger adolescents vs 3 doses in young women: a randomized clinical trial. JAMA. 2013;309(17):1793–802. doi:10.1001/jama.2013.1625.
   PubMed Web of Science ®Google Scholar
• Romanowski B, Schwarz TF, Ferguson L, Peters K, Dionne M, Behre U, Schulze K, Hillemanns P, Suryakiran P, Thomas F, et al. Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: five-year clinical data and modeling predictions from a randomized study. Hum Vaccin Immunother. 2016;12(1):20–29. doi:10.1080/21645515.2015.1065363.
   PubMed Web of Science ®Google Scholar
• Ferris D, Samakoses R, Block SL, Lazcano-Ponce E, Restrepo JA, Reisinger KS, Mehlsen J, Chatterjee A, Iversen O-E, Sings HL, et al. Long-term study of a quadrivalent human papillomavirus vaccine. Pediatrics. 2014;134(3):e657–665. doi:10.1542/peds.2013-4144.
   PubMed Web of Science ®Google Scholar
• Schwarz TF, Spaczynski M, Schneider A, Wysocki J, Galaj A, Schulze K, Poncelet SM, Catteau G, Thomas F, Descamps D. Persistence of immune response to HPV-16/18 AS04-adjuvanted cervical cancer vaccine in women aged 15–55 years. Hum Vaccin. 2011;7(9):958–65. doi:10.4161/hv.7.9.15999.
   PubMed Web of Science ®Google Scholar
• Stokley S, Jeyarajah J, Yankey D, Cano M, Gee J, Roark J, Curtis RC, Markowitz L. Human papillomavirus vaccination coverage among adolescents, 2007–2013, and postlicensure vaccine safety monitoring, 2006–2014–United States. MMWR Morb Mortality Weekly Rep. 2014;63:620–24.
   PubMed Web of Science ®Google Scholar
• Abma JC, Martinez GM. Sexual activity and contraceptive use among teenagers in the United States, 2011–2015. Hyattsville (MD): National Center for Health Statistics; 2017.
   Google Scholar
• Kann L, McManus T, Harris WA, Shanklin SL, Flint KH, Queen B, Lowry R, Chyen D, Whittle L, Thornton J, et al. Youth risk behavior surveillance - United States 2017. MMWR Surveill Summ 2018. 2018;67(8):1–114. doi:10.15585/mmwr.ss6708a1.
   PubMed Web of Science ®Google Scholar
• Centers for Disease Control and Prevention. Genital HPV infection - fact sheet. 2017 [ accessed 2018 Sept 30]. https://www.cdc.gov/std/hpv/stdfact-hpv.htm.
   Google Scholar
• Doorbar J, Quint W, Banks L, Bravo IG, Stoler M, Broker TR, Stanley MA. The biology and life-cycle of human papillomaviruses. Vaccine. 2012;30(Suppl 5):F55–70. doi:10.1016/j.vaccine.2012.06.083.
   PubMed Web of Science ®Google Scholar
• Liu Z, Rashid T, Nyitray AG. Penises not required: a systematic review of the potential for human papillomavirus horizontal transmission that is non-sexual or does not include penile penetration. Sex Health. 2016;13(1):10–21. doi:10.1071/SH15089.
   PubMed Web of Science ®Google Scholar
• Coles VA, Patel AS, Allen FL, Keeping ST, Carroll SM. The association of human papillomavirus vaccination with sexual behaviours and human papillomavirus knowledge: a systematic review. Int J STD AIDS. 2015;26(11):777–88. doi:10.1177/0956462414554629.
   PubMed Web of Science ®Google Scholar
• Mullins TL, Widdice LE, Rosenthal SL, Zimet GD, Kahn JA. Risk perceptions, sexual attitudes, and sexual behavior after HPV vaccination in 11–12 year-old girls. Vaccine. 2015;33(32):3907–12. doi:10.1016/j.vaccine.2015.06.060.
   PubMed Web of Science ®Google Scholar
• Rysavy MB, Kresowik JD, Liu D, Mains L, Lessard M, Ryan GL. Human papillomavirus vaccination and sexual behavior in young women. J Pediatr Adolesc Gynecol. 2014;27(2):67–71. doi:10.1016/j.jpag.2013.08.009.
   PubMed Web of Science ®Google Scholar
• Petrosky EY, Liu G, Hariri S, Markowitz LE. Human papillomavirus vaccination and age at first sexual activity, national health and nutrition examination survey. Clin Pediatr (Phila). 2017;56(4):363–70. doi:10.1177/0009922816660541.
   PubMed Web of Science ®Google Scholar
• Liddon NC, Leichliter JS, Markowitz LE. Human papillomavirus vaccine and sexual behavior among adolescent and young women. Am J Prev Med. 2012;42(1):44–52. doi:10.1016/j.amepre.2011.09.024.
   PubMed Web of Science ®Google Scholar
• Jena AB, Goldman DP, Seabury SA. Incidence of sexually transmitted infections after human papillomavirus vaccination among adolescent females. JAMA Intern Med. 2015;175(4):617–23. doi:10.1001/jamainternmed.2014.7886.
   PubMed Web of Science ®Google Scholar
• Bednarczyk RA, Davis R, Ault K, Orenstein W, Omer SB. Sexual activity-related outcomes after human papillomavirus vaccination of 11- to 12-year-olds. Pediatrics. 2012;130(5):798–805. doi:10.1542/peds.2012-1516.
   PubMed Web of Science ®Google Scholar
• Smith LM, Kaufman JS, Strumpf EC, Levesque LE. Effect of human papillomavirus (HPV) vaccination on clinical indicators of sexual behaviour among adolescent girls: the Ontario Grade 8 HPV Vaccine Cohort Study. CMAJ. 2015;187(2):E74–81. doi:10.1503/cmaj.140900.
   PubMed Web of Science ®Google Scholar
• Kasting ML, Shapiro GK, Rosberger Z, Kahn JA, Zimet GD. Tempest in a teapot: A systematic review of HPV vaccination and risk compensation research. Hum Vaccin Immunother. 2016;12(6):1435–50. doi:10.1080/21645515.2016.1141158.
   PubMed Web of Science ®Google Scholar
• Gualano MR, Bert F, Voglino G, Buttinelli E, D’Errico MM, De Waure C, Di Giovanni P, Fantini MP, Giuliani AR, Marranzano M, et al. Attitudes towards compulsory vaccination in Italy: results from the NAVIDAD multicentre study. Vaccine. 2018;36(23):3368–74. doi:10.1016/j.vaccine.2018.04.029.
   PubMed Web of Science ®Google Scholar
• Vannice KS, Salmon DA, Shui I, Omer SB, Kissner J, Edwards KM, Sparks R, Dekker CL, Klein NP, Gust DA. Attitudes and beliefs of parents concerned about vaccines: impact of timing of immunization information. Pediatrics. 2011;127(Suppl 1):S120–126. doi:10.1542/peds.2010-1722R.
   PubMed Web of Science ®Google Scholar
• Betsch C, Bodeker B, Schmid P, Wichmann O. How baby’s first shot determines the development of maternal attitudes towards vaccination. Vaccine. 2018;36(21):3018–26. doi:10.1016/j.vaccine.2018.04.023.
   PubMed Web of Science ®Google Scholar
• Bednarczyk RA, Chamberlain A, Mathewson K, Salmon DA, Omer SB. Practice-, Provider-, and Patient-level interventions to improve preventive care: development of the P3 model. Preventive Med Rep. 2018;11:131–38. doi:10.1016/j.pmedr.2018.06.009.
   PubMedGoogle Scholar
• Brewer NT, Hall ME, Malo TL, Gilkey MB, Quinn B, Lathren C. Announcements versus conversations to improve HPV vaccination coverage: a randomized trial. Pediatrics. 2017;139(1). doi: 10.1542/peds.2016-1764
   PubMed Web of Science ®Google Scholar
• Beavis A, Krakow M, Levinson K, Rositch AF. Reasons for lack of HPV vaccine initiation in NIS-teen over time: shifting the focus from gender and sexuality to necessity and safety. J Adolesc Health. 2018;63(5):652–56. doi:10.1016/j.jadohealth.2018.06.024.
   PubMed Web of Science ®Google Scholar
• Dunn AG, Surian D, Leask J, Dey A, Mandl KD, Coiera E. Mapping information exposure on social media to explain differences in HPV vaccine coverage in the United States. Vaccine. 2017;35(23):3033–40. doi:10.1016/j.vaccine.2017.04.060.
   PubMed Web of Science ®Google Scholar
• Faasse K, Porsius JT, Faasse J, Martin LR. Bad news: the influence of news coverage and Google searches on Gardasil adverse event reporting. Vaccine. 2017;35(49 Pt B):6872–78. doi:10.1016/j.vaccine.2017.10.004.
   PubMed Web of Science ®Google Scholar
• Kang GJ, Ewing-Nelson SR, Mackey L, Schlitt JT, Marathe A, Abbas KM, Swarup S. Semantic network analysis of vaccine sentiment in online social media. Vaccine. 2017;35(29):3621–38. doi:10.1016/j.vaccine.2017.05.052.
   PubMed Web of Science ®Google Scholar
• Keim-Malpass J, Mitchell EM, Sun E, Kennedy C. Using Twitter to understand public perceptions regarding the #HPV vaccine: opportunities for public health nurses to engage in social marketing. Public Health Nurs. 2017;34(4):316–23. doi:10.1111/phn.12318.
   PubMed Web of Science ®Google Scholar
• Surian D, Nguyen DQ, Kennedy G, Johnson M, Coiera E, Dunn AG. Characterizing Twitter discussions about HPV vaccines using topic modeling and community detection. J Med Internet Res. 2016;18(8):e232. doi:10.2196/jmir.6045.
   PubMed Web of Science ®Google Scholar
• Jarrett C, Wilson R, O’Leary M, Eckersberger E, Larson HJ. Strategies for addressing vaccine hesitancy - a systematic review. Vaccine. 2015;33(34):4180–90. doi:10.1016/j.vaccine.2015.04.040.
   PubMed Web of Science ®Google Scholar
• Cook J, Lewandowsky S. The debunking handbook. 2012 [ accessed 2018 Sept 27]. https://skepticalscience.com/docs/Debunking_Handbook.pdf.
   Google Scholar